Title |
Genetically Modified T Cells to Target Glioblastoma
|
---|---|
Published in |
Frontiers in oncology, January 2013
|
DOI | 10.3389/fonc.2013.00322 |
Pubmed ID | |
Authors |
Simone Krebs, Tania G. Rodríguez-Cruz, Christopher DeRenzo, Stephen Gottschalk |
Abstract |
Despite advances in surgical procedures, radiation, and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressive microenvironment. The advent of gene transfer has allowed the rapid generation of antigen-specific T cells as well as T cells with enhanced effector function. Here we review recent advances in the field of cell therapy with genetically modified T cells and how these advances might improve outcomes for patients with GBM in the future. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 2% |
Switzerland | 1 | 2% |
Unknown | 43 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 22% |
Student > Bachelor | 9 | 20% |
Student > Ph. D. Student | 7 | 16% |
Student > Master | 5 | 11% |
Student > Postgraduate | 4 | 9% |
Other | 5 | 11% |
Unknown | 5 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 14 | 31% |
Medicine and Dentistry | 11 | 24% |
Biochemistry, Genetics and Molecular Biology | 6 | 13% |
Immunology and Microbiology | 3 | 7% |
Neuroscience | 2 | 4% |
Other | 4 | 9% |
Unknown | 5 | 11% |